HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CTFA on antimicrobials

This article was originally published in The Rose Sheet

Executive Summary

Prescription antibiotics, not antimicrobial personal care products cause bacterial resistance, the Cosmetics Toiletry and Fragrance Association and the Soap and Detergent Association say in a joint statement. The "real culprit" of microbial resistance is the "over-prescription and misuse of antibiotics," the trade groups maintain. CTFA and SDA also respond to recent media statements by Stuart Levy, MD, Tufts University that antibacterial personal care products create resistance and should only be used by seriously ill people or those with low immunity. Levy "has oversimplified a very complex scientific debate and, most importantly, is not focusing on the proven reasons for antibiotic resistance," CTFA contends. CTFA and an FDA coalition separately are studying the issue (1"The Rose Sheet" June 12, In Brief, 2June 26, p. 8)

Prescription antibiotics, not antimicrobial personal care products cause bacterial resistance, the Cosmetics Toiletry and Fragrance Association and the Soap and Detergent Association say in a joint statement. The "real culprit" of microbial resistance is the "over-prescription and misuse of antibiotics," the trade groups maintain. CTFA and SDA also respond to recent media statements by Stuart Levy, MD, Tufts University that antibacterial personal care products create resistance and should only be used by seriously ill people or those with low immunity. Levy "has oversimplified a very complex scientific debate and, most importantly, is not focusing on the proven reasons for antibiotic resistance," CTFA contends. CTFA and an FDA coalition separately are studying the issue (1 (Also see "CTFA on antibacterials" - HBW Insight, 12 Jun, 2000.), 2 (Also see "OTC Antimicrobial Resistance Study Subject Of FDA, NIH, CDC "Action Plan"" - HBW Insight, 26 Jun, 2000.)).

Latest Headlines
See All
UsernamePublicRestriction

Register

RS008278

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel